Product Description
OnQuality is developing OQL025, a Janus Kinase (JAK) inhibitor administered as a topical cream, and OQL06x, an oral gut-restricted JAK inhibitor. Topical OQL025 delayed the onset and the severity of EGFR inhibitor-induced rash with low systemic exposure in preclinical models. In murine models of diarrhea caused by afatanib, orally administered OQL06x reduced the severity of EGFR inhibitor-induced diarrhea when compared to placebo. (Sourced from: https://www.benzinga.com/pressreleases/23/04/n31852632/onquality-pharmaceuticals-presented-preclinical-data-for-oql025-and-oql06x-novel-therapeutics-for-)
Mechanisms of Action: JAK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: OnQuality Pharmaceuticals
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Diarrhea
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|